 Philip Breen
Concepts (120)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cyclodextrins | 2 | 2015 | 17 | 1.100 |
Why?
| | Excipients | 2 | 2015 | 8 | 1.100 |
Why?
| | Chemistry, Pharmaceutical | 3 | 2015 | 39 | 0.740 |
Why?
| | Pharmaceutical Preparations | 1 | 2013 | 86 | 0.440 |
Why?
| | Gastrointestinal Tract | 1 | 2013 | 134 | 0.420 |
Why?
| | Asteraceae | 2 | 2022 | 11 | 0.310 |
Why?
| | Solubility | 2 | 2015 | 74 | 0.250 |
Why?
| | Anti-Bacterial Agents | 4 | 2015 | 825 | 0.240 |
Why?
| | Sesquiterpenes | 2 | 2016 | 91 | 0.230 |
Why?
| | Morphine Derivatives | 1 | 2021 | 30 | 0.190 |
Why?
| | Morphine | 1 | 2021 | 95 | 0.190 |
Why?
| | Molecular Structure | 3 | 2016 | 319 | 0.180 |
Why?
| | Biological Availability | 3 | 2013 | 131 | 0.160 |
Why?
| | Digoxin | 2 | 2006 | 32 | 0.140 |
Why?
| | Dosage Forms | 1 | 2015 | 9 | 0.140 |
Why?
| | Cimicifuga | 2 | 2006 | 8 | 0.140 |
Why?
| | Durapatite | 1 | 2015 | 27 | 0.140 |
Why?
| | Drug Carriers | 1 | 2015 | 82 | 0.130 |
Why?
| | Vancomycin | 1 | 2015 | 88 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 192 | 0.130 |
Why?
| | Nuclear Family | 1 | 2014 | 14 | 0.130 |
Why?
| | Osteomyelitis | 1 | 2015 | 124 | 0.120 |
Why?
| | Administration, Oral | 2 | 2013 | 461 | 0.120 |
Why?
| | Permeability | 1 | 2013 | 87 | 0.120 |
Why?
| | Tocotrienols | 1 | 2013 | 42 | 0.120 |
Why?
| | Intestinal Absorption | 1 | 2013 | 60 | 0.120 |
Why?
| | Vitamin E | 1 | 2013 | 107 | 0.110 |
Why?
| | Students | 1 | 2014 | 207 | 0.110 |
Why?
| | Radiation-Protective Agents | 1 | 2013 | 116 | 0.110 |
Why?
| | Clarithromycin | 3 | 2006 | 40 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2013 | 360 | 0.100 |
Why?
| | Rifampin | 3 | 2006 | 57 | 0.100 |
Why?
| | Staphylococcus aureus | 2 | 2015 | 363 | 0.100 |
Why?
| | Methicillin Resistance | 1 | 2011 | 25 | 0.100 |
Why?
| | Lactones | 1 | 2011 | 27 | 0.100 |
Why?
| | Smoking | 1 | 2014 | 552 | 0.090 |
Why?
| | Herb-Drug Interactions | 2 | 2006 | 30 | 0.090 |
Why?
| | Cytochrome P-450 CYP3A | 2 | 2006 | 82 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1300 | 0.080 |
Why?
| | Liver | 1 | 2013 | 1226 | 0.080 |
Why?
| | Kava | 1 | 2006 | 10 | 0.070 |
Why?
| | Hydrastis | 1 | 2006 | 10 | 0.070 |
Why?
| | Humans | 10 | 2016 | 54304 | 0.070 |
Why?
| | Antibiotics, Antitubercular | 1 | 2006 | 14 | 0.070 |
Why?
| | Rats | 3 | 2021 | 3417 | 0.070 |
Why?
| | Cardiotonic Agents | 1 | 2006 | 95 | 0.070 |
Why?
| | Pyridinium Compounds | 1 | 2005 | 17 | 0.070 |
Why?
| | Plant Preparations | 1 | 2005 | 38 | 0.070 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2005 | 29 | 0.070 |
Why?
| | Cetylpyridinium | 1 | 2005 | 4 | 0.070 |
Why?
| | Malus | 1 | 2005 | 5 | 0.070 |
Why?
| | Dietary Supplements | 2 | 2006 | 452 | 0.070 |
Why?
| | Drug Residues | 1 | 2005 | 9 | 0.060 |
Why?
| | Models, Molecular | 3 | 2013 | 423 | 0.060 |
Why?
| | Anti-Infective Agents | 1 | 2005 | 111 | 0.060 |
Why?
| | Aerosol Propellants | 1 | 2003 | 5 | 0.060 |
Why?
| | Adrenergic beta-Agonists | 1 | 2003 | 43 | 0.060 |
Why?
| | Metered Dose Inhalers | 1 | 2003 | 19 | 0.060 |
Why?
| | Chromatography, Thin Layer | 1 | 2022 | 32 | 0.050 |
Why?
| | Albuterol | 1 | 2003 | 58 | 0.050 |
Why?
| | Plants | 1 | 2022 | 54 | 0.050 |
Why?
| | Animals | 4 | 2021 | 14402 | 0.050 |
Why?
| | Area Under Curve | 3 | 2006 | 205 | 0.050 |
Why?
| | Half-Life | 2 | 2013 | 92 | 0.050 |
Why?
| | Plant Extracts | 1 | 2022 | 192 | 0.040 |
Why?
| | Drug Design | 2 | 2013 | 133 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2011 | 290 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2021 | 1664 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 142 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 2016 | 115 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2016 | 477 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2016 | 371 | 0.030 |
Why?
| | Debridement | 1 | 2015 | 54 | 0.030 |
Why?
| | Drug Interactions | 2 | 2006 | 206 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2016 | 423 | 0.030 |
Why?
| | Male | 5 | 2021 | 27335 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2015 | 107 | 0.030 |
Why?
| | Imitative Behavior | 1 | 2014 | 9 | 0.030 |
Why?
| | District of Columbia | 1 | 2014 | 23 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 657 | 0.030 |
Why?
| | Molecular Dynamics Simulation | 1 | 2013 | 40 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2013 | 237 | 0.030 |
Why?
| | Family | 1 | 2014 | 190 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 1476 | 0.030 |
Why?
| | Binding Sites | 1 | 2013 | 440 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2016 | 1097 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 302 | 0.030 |
Why?
| | Brain | 1 | 2021 | 1391 | 0.030 |
Why?
| | Bone and Bones | 1 | 2015 | 515 | 0.030 |
Why?
| | Plant Components, Aerial | 1 | 2011 | 5 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2011 | 80 | 0.030 |
Why?
| | Prevalence | 1 | 2014 | 1026 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2011 | 178 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2011 | 255 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2015 | 1651 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 1693 | 0.020 |
Why?
| | Enzyme Activators | 1 | 2006 | 8 | 0.020 |
Why?
| | Midazolam | 1 | 2006 | 42 | 0.020 |
Why?
| | Genes, MDR | 1 | 2005 | 4 | 0.020 |
Why?
| | Food Preservatives | 1 | 2005 | 4 | 0.020 |
Why?
| | Salmonella typhimurium | 1 | 2005 | 54 | 0.020 |
Why?
| | Adult | 3 | 2006 | 14189 | 0.020 |
Why?
| | Mice | 1 | 2016 | 6428 | 0.020 |
Why?
| | Food Microbiology | 1 | 2005 | 48 | 0.020 |
Why?
| | Haplotypes | 1 | 2005 | 105 | 0.020 |
Why?
| | Hypnotics and Sedatives | 1 | 2006 | 74 | 0.020 |
Why?
| | Calibration | 1 | 2005 | 59 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 401 | 0.020 |
Why?
| | Young Adult | 1 | 2014 | 4313 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2006 | 213 | 0.020 |
Why?
| | Escherichia coli | 1 | 2005 | 251 | 0.010 |
Why?
| | United States | 1 | 2014 | 5204 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 445 | 0.010 |
Why?
| | Software | 1 | 2005 | 297 | 0.010 |
Why?
| | Phenotype | 1 | 2006 | 820 | 0.010 |
Why?
| | Adolescent | 1 | 2014 | 6896 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 922 | 0.010 |
Why?
| | Child | 1 | 2014 | 7372 | 0.010 |
Why?
| | Female | 3 | 2006 | 28457 | 0.010 |
Why?
| | Asthma | 1 | 2003 | 293 | 0.010 |
Why?
|
|
Breen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|